Next Article in Journal
Cellulose Nanomaterials—Binding Properties and Applications: A Review
Next Article in Special Issue
In Silico Prediction of O6-Methylguanine-DNA Methyltransferase Inhibitory Potency of Base Analogs with QSAR and Machine Learning Methods
Previous Article in Journal
Melt Viscoelastic Assessment of Poly(Lactic Acid) Composting: Influence of UV Ageing
Previous Article in Special Issue
The Targeted Pesticides as Acetylcholinesterase Inhibitors: Comprehensive Cross-Organism Molecular Modelling Studies Performed to Anticipate the Pharmacology of Harmfulness to Humans In Vitro
Article

Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation

1
School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan
2
Department of Hospital Pharmacy, University of Toyama, 2630 Sugitani, Toyama 930-0194, Japan
*
Authors to whom correspondence should be addressed.
Molecules 2018, 23(10), 2683; https://doi.org/10.3390/molecules23102683
Received: 10 September 2018 / Revised: 11 October 2018 / Accepted: 18 October 2018 / Published: 18 October 2018
(This article belongs to the Special Issue Application of Computational Methods in Drug Design)
Some point mutations in β-glucocerebrosidase cause either improper folding or instability of this protein, resulting in Gaucher disease. Pharmacological chaperones bind to the mutant enzyme and stabilize this enzyme; thus, pharmacological chaperone therapy was proposed as a potential treatment for Gaucher disease. The binding affinities of α-1-C-alkyl 1,4-dideoxy-1,4-imino-d-arabinitol (DAB) derivatives, which act as pharmacological chaperones for β-glucocerebrosidase, abruptly increased upon elongation of their alkyl chain. In this study, the primary causes of such an increase in binding affinity were analyzed using protein–ligand docking and molecular dynamics simulations. We found that the activity cliff between α-1-C-heptyl-DAB and α-1-C-octyl-DAB was due to the shape and size of the hydrophobic binding site accommodating the alkyl chains, and that the interaction with this hydrophobic site controlled the binding affinity of the ligands well. Furthermore, based on the aromatic/hydrophobic properties of the binding site, a 7-(tetralin-2-yl)-heptyl-DAB compound was designed and synthesized. This compound had significantly enhanced activity. The design strategy in consideration of aromatic interactions in the hydrophobic pocket was useful for generating effective pharmacological chaperones for the treatment of Gaucher disease. View Full-Text
Keywords: pharmacological chaperone; Gaucher disease; ligand docking; molecular dynamics; drug design pharmacological chaperone; Gaucher disease; ligand docking; molecular dynamics; drug design
Show Figures

Graphical abstract

MDPI and ACS Style

Nakagome, I.; Kato, A.; Yamaotsu, N.; Yoshida, T.; Ozawa, S.-i.; Adachi, I.; Hirono, S. Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation. Molecules 2018, 23, 2683. https://doi.org/10.3390/molecules23102683

AMA Style

Nakagome I, Kato A, Yamaotsu N, Yoshida T, Ozawa S-i, Adachi I, Hirono S. Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation. Molecules. 2018; 23(10):2683. https://doi.org/10.3390/molecules23102683

Chicago/Turabian Style

Nakagome, Izumi, Atsushi Kato, Noriyuki Yamaotsu, Tomoki Yoshida, Shin-ichiro Ozawa, Isao Adachi, and Shuichi Hirono. 2018. "Design of a New α-1-C-Alkyl-DAB Derivative Acting as a Pharmacological Chaperone for β-Glucocerebrosidase Using Ligand Docking and Molecular Dynamics Simulation" Molecules 23, no. 10: 2683. https://doi.org/10.3390/molecules23102683

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop